Search Results

A Prospective Low-interventional Phase 4 Single Arm Study Of Ocular Assessments In Patients Treated With Tivdak® In Recurrent Or Metastatic Cervical Cancer MOA: Tisotumab vedotin-tftv (Tivdak®) is a tissue factor (TF)-directed ADC with an MMAE payload. Key Eligibility: Recurrent/metastatic cervical cancer with PD on/afterchemotherapy Tivdak recommended by physician according to US prescribinginformation Must be willing…

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation MOA: Rezatapopt (PC14586) is a p53 reactivator that selectively binds to the mutated p53 Y220C protein and restores p53 WT activity. Key Eligibility Histologically…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER 050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) MOA: Elritercept is a recombinant fusion protein designed to inhibit signaling by select TGF-β superfamily ligands, including activin A,…

A Phase 1b Clinical Study of NXP900 in Combination with Osimertinib in Subjects with Advanced, EGFRMut+ Non-Small Cell Lung Cancer (NXP900-103) MOA: NXP900 is an orally bioavailable small molecular and potent inhibitor of kinases from the SRC family of kinases (SFK). Key Eligibility: Unresectable, met/LA EGFRMut+ NSCLC Plasma or tissue may be used for ctDNA,…

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) MOA: Adagrasib is an oral, selective inhibitor of KRASG12C mutant Key Eligibility: Histologically or cytologically confirmed diagnosis…

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K) alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors MOA: TOS-358 is a covalent inhibitor of WT and mutant PI3Kα and has much better toxicity profile compared to other inhibitors in this class Key Eligibility: HR+/HER2- LA/rec or MBC with PIK3CA…